Executive Overview
Ireland hosts one of the world’s highest concentrations of advanced biologics manufacturing facilities. This case study reflects a brownfield expansion of an operational sterile manufacturing campus operating at greater than 90% utilisation.
The programme was initiated to protect €180M+ in annual EU revenue exposure following expanded therapeutic indications for a monoclonal antibody product. Capacity constraints across upstream bioreactors and downstream purification required a controlled expansion without disrupting live GMP production.
Delivery required simultaneous orchestration across engineering design, cleanroom construction, long-lead equipment procurement, automation integration, full CQV lifecycle execution, inspection readiness, and capital governance control.
Programme Snapshot
| Programme Type | Brownfield Expansion (Live GMP Site) |
|---|---|
| Location | West Dublin Manufacturing Campus |
| Capital Investment | €180 Million |
| Timeline | 24 Months |
| Regulatory Oversight | HPRA (EU) + FDA (US) |
| Delivery Model | Stage-Gate Capital Governance + Agile Automation Streams |
Strategic Objectives
- Increase sterile biologics production capacity by approximately 38%
- Protect €180M annual EU revenue exposure
- Maintain uninterrupted existing commercial production
- Ensure full compliance with EU GMP Annex 1 and FDA 21 CFR Part 210/211
- Enable regulatory inspection approval within original window
Scope Summary
In Scope:
- Installation of 2 × 20,000L stainless steel upstream bioreactors
- New downstream purification skid and chromatography systems
- ISO 7 cleanroom expansion
- Utilities extension (WFI, Clean Steam, HVAC)
- Automation integration and CSV validation
- Full Commissioning, Qualification & Validation (CQV)
- HPRA & FDA inspection readiness
Out of Scope:
- R&D process development changes
- Global supply chain redesign
- Packaging and distribution network modification
Key Delivery Highlights
- Major equipment FAT deviation resolved without replacement
- Schedule impact reduced from 12-week risk to 3-week containment
- 0 Critical regulatory findings
- Commercial release approved within planned regulatory window
Programme Artifacts
Programme Context
Strategic ViewIndustry positioning, Irish biologics ecosystem, brownfield complexity, and regulatory landscape.
Project Charter
GovernanceFormal objectives, business case, success metrics, stakeholder model, and milestone plan.
Governance Model
Control StructureSteering cadence, capital control, change governance, and reporting rhythm.
Integrated Master Schedule
SchedulingCritical path analysis, dependency management, float tracking, and buffer control.
Risk Register (RAG)
Risk GovernanceCategorised risk log covering technical, regulatory, operational and financial exposures.
Cost & Resourcing
Financial ControlCapital allocation, earned value control, contingency governance and resourcing structure.
Inspection Readiness
RegulatoryMock audits, audit-room model, SME allocation, documentation index and inspection outcome.
Lessons Learned
ReflectionDelivery insights, regulatory leadership lessons, and Irish market realities.
Disclaimer
Portfolio NoteConfidentiality statement and educational-use clarification.